(This article was updated in June 2018)
The advent of transcatheter valve repair and replacement technologies is one of those rare instances where there is a rapid paradigm shift in medicine. Since the first transcatheter aortic valve replacement (TAVR) systems were cleared by the U.S. Food and Drug Administration (FDA) in 2011Â (Edwards Lifesciences Sapien) and 2014 (Medtronic CoreValve), TAVR rapidly expanded. It is also fueling enthusiasm for new transcatheter mitral valve replacement (TMVR) technology.
